---
id: splenic-abscess-multiloculated_169
category: radiology
tags: [splenic-abscess, spleen, CT, immunocompromised, endocarditis]
deck: Infectious Diseases
created: 2025-11-11
modified: 2025-11-11
---

## Splenic Abscess - Multiloculated

**Q:** What are the characteristic CT/MRI findings of splenic abscess, what are the risk factors and sources, and when is splenectomy indicated?

**A:**

## DEFINITION

**Splenic Abscess:** **"Localized collection of pus within splenic parenchyma"**

**CT Hallmark:** **Rim-enhancing hypodense lesion(s) in spleen, often multiloculated**

**Key Point:** **Splenic abscess = rare but life-threatening** (40-70% mortality if untreated)

---

## EPIDEMIOLOGY

**Incidence:** Rare (0.14-0.7% of autopsies)

**Risk Factors:**

**Mnemonic: "IMMUNOCOMPROMISED-ENDOCARDITIS-TRAUMA-HEMOGLOBINOPATHY"**

**Immunocompromised (Most Common - 50-70%):**
- **HIV/AIDS**
- **Chemotherapy** (neutropenia)
- **Organ transplant** (immunosuppression)
- **Corticosteroids** (chronic high-dose)
- **Diabetes mellitus**

**Endocarditis (20-30%):**
- **Bacterial endocarditis** (#1 cause in immunocompetent)
- **Septic emboli** to spleen
- **IVDU** (tricuspid endocarditis)

**Trauma (10-15%):**
- **Blunt trauma** (splenic laceration → superinfection)
- **Penetrating trauma** (gunshot, stab)

**Hemoglobinopathy (10-15%):**
- **Sickle cell disease** (splenic infarct → superinfection)
- **Hemolytic anemia**

**Other:**
- **Splenic infarct** (superinfection)
- **Contiguous spread** (pancreatitis, perinephric abscess, colon)

**Key Point:** **Immunocompromised = #1 risk factor** (50-70%) | **Endocarditis = #1 in immunocompetent**

---

## PATHOPHYSIOLOGY

**Routes of Infection:**

**Mnemonic: "HEMATOGENOUS-CONTIGUOUS-TRAUMA"**

**Hematogenous (Most Common - 60-70%):**
- **Endocarditis** (septic emboli - #1 source)
- **Bacteremia** (from any source)
- **Septic emboli** (from cardiac vegetation, catheter)

**Contiguous Spread (10-20%):**
- **Pancreatitis** (adjacent, splenic vein thrombosis)
- **Perinephric abscess** (left kidney)
- **Colon** (splenic flexure perforation - diverticulitis, colon cancer)
- **Gastric** (penetrating ulcer)

**Trauma (10-15%):**
- **Blunt trauma** (splenic laceration → hematoma → superinfection)
- **Penetrating trauma**

**Infarction (5-10%):**
- **Splenic infarct** → superinfection (sickle cell, embolic infarct)

**Key Point:** **Hematogenous = most common** (60-70%, endocarditis #1 source)

---

## CT FINDINGS (Gold Standard)

**CT = Preferred Modality**

**Hallmark: Rim-Enhancing Hypodense Lesion**

---

### **CT WITH CONTRAST FINDINGS:**

**Mnemonic: "RIM-ENHANCE-MULTILOCULATED-GAS"**

**Abscess:**
- **Hypodense lesion** (10-30 HU - pus, necrosis)
- **Rim enhancement** (abscess wall - vascularized granulation tissue)
- **Central non-enhancing** (purulent fluid)
- **Multiloculated** (50-70% - **hallmark**, multiple septated compartments)
- **Gas bubbles** (if gas-forming organism - 10-20%)
- **Irregular margins**

**R**im enhancement (hallmark)
**I**rregular rim
**M**arked peripheral enhancement

**E**nhancing wall (granulation tissue)
**N**on-enhancing center (pus)
**H**ypodense collection (10-30 HU)
**A**bscess cavity
**N**ecrotic center
**C**avity fluid
**E**nlargement (splenomegaly)

**M**ultiloculated (50-70% - HALLMARK)
**U**sually multiple septations
**L**ocules (compartments)
**T**hick septations
**I**nternal septations enhance
**L**arge or small abscesses
**O**ften multiple (vs solitary)
**C**omplex appearance
**U**neven enhancement
**L**esions (multiple)
**A**djacent collections
**T**hickened walls
**E**nhancing septations
**D**ivided cavities

**G**as bubbles (10-20%, if gas-forming organism)
**A**ir-fluid levels (if large)
**S**uggest anaerobes (or bowel communication)

**Additional Findings:**
- **Splenomegaly** (enlarged spleen)
- **Splenic infarct** (wedge-shaped non-enhancing area - if embolic)
- **Perisplen ic fluid** (if rupture)
- **Left pleural effusion** (reactive, sympathetic)
- **Ascites** (if severe infection)

**Key Point:** **Multiloculated rim-enhancing hypodense lesion = splenic abscess** (50-70% multiloculated)

---

### **UNENHANCED CT:**

- **Hypodense mass** (fluid attenuation)
- **Gas bubbles** (if present)
- **Cannot distinguish from cyst or infarct** without contrast

**Key Point:** **Contrast essential** to confirm abscess (rim enhancement)

---

## MRI FINDINGS

**MRI Characteristics:**

**T1:**
- **Hypointense lesion** (pus - low signal)
- **Rim:** Variable signal

**T2:**
- **Hyperintense lesion** (very bright - pus, edema)
- **Rim:** Hypointense (fibrous capsule)
- **Septations:** Hypointense (fibrous)

**Post-contrast T1 Fat-Saturated:**
- **Rim enhancement** (abscess wall)
- **Septations enhance**
- **Central non-enhancing** (pus)

**DWI/ADC:**
- **DWI hyperintense** (restricted diffusion - purulent abscess)
- **ADC hypointense** (low ADC values)
- **Confirms purulent nature**

**Key Point:** **MRI less commonly used** (CT faster, more available for acute abdomen)

---

## ULTRASOUND FINDINGS

**Findings:**
- **Hypoechoic to anechoic collection** (fluid)
- **Echogenic debris** (internal echoes from pus, septations)
- **Posterior acoustic enhancement** (fluid-filled structure)
- **Thick irregular wall**
- **Septations** (if multiloculated)

**Limitations:**
- **Left upper quadrant location** (obscured by ribs, bowel gas)
- **Operator-dependent**

**Key Point:** **CT superior** to ultrasound (better visualization, more sensitive)

---

## SOLITARY vs MULTIPLE ABSCESSES

**Solitary Abscess (30-50%):**
- **Larger size** (often >5 cm)
- **Often multiloculated** (septations within single abscess)

**Multiple Abscesses (50-70%):**
- **Microabscesses** (small, <1 cm)
- **Immunocompromised** (fungal, mycobacterial)
- **Septic emboli** (endocarditis)
- **Disseminated infection** (hematogenous)

**Key Point:** **Multiple abscesses = immunocompromised or endocarditis**

---

## CLINICAL PRESENTATION

**Symptoms:**
- **Fever** (90-95%)
- **Left upper quadrant pain** (70-80%)
- **Chills** (60-70%)
- **Nausea/vomiting** (40-50%)
- **Left shoulder pain** (if diaphragm irritation - Kehr sign)

**Physical Exam:**
- **Tender splenomegaly** (60-70%)
- **Guarding** (left upper quadrant)
- **Left pleural effusion** (crackles, dullness - 30-40%)

**Nonspecific Presentation:**
- **Often insidious** (weeks)
- **May mimic splenic infarct, abscess, tumor**

**Key Point:** **Fever + LUQ pain + tender splenomegaly = splenic abscess** (but often nonspecific)

---

## LABS

**Inflammatory Markers:**
- **WBC elevated** (leukocytosis 70-90%)
- **CRP/ESR elevated** (90-95%)
- **Thrombocytopenia** (30-50%, splenic sequestration or sepsis)
- **Anemia** (chronic inflammation)

**Blood Cultures:**
- **Positive 40-70%** (hematogenous source)

**Key Point:** **Blood cultures positive 40-70%** (hematogenous spread)

---

## ORGANISMS

**Mnemonic: "STAPH-STREP-GRAM-NEG-FUNGAL-TB"**

**Immunocompetent (Endocarditis):**
- ***Staphylococcus aureus*** (30-40% - most common)
- **Streptococcus** species (Viridans, S. pneumoniae - 20-30%)
- **Gram-negatives** (E. coli, Salmonella - 15-20%)
- **Anaerobes** (if contiguous GI source - 10-15%)
- **Polymicrobial** (20-30%)

**Immunocompromised:**
- **Fungi** (30-50% in neutropenic):
  - ***Candida*** species (most common fungal)
  - ***Aspergillus***
  - **Mucormycosis** (rare)
- ***Mycobacterium tuberculosis*** (TB - 5-10%, endemic areas)
- ***Mycobacterium avium complex*** (MAC - HIV/AIDS)
- **Bacteria** (S. aureus, Gram-negatives)

**Sickle Cell Disease:**
- ***Salmonella*** species (30-50% - splenic infarct superinfection)

**Key Point:** **Immunocompetent = S. aureus, Strep** | **Immunocompromised = Fungi (Candida, Aspergillus)**

---

## DIAGNOSIS

**Imaging:**
- **CT with contrast** (gold standard - 90-95% sensitive)
- **MRI with DWI** (if CT contraindicated)
- **Ultrasound** (bedside, but limited)

**Blood Cultures:**
- **Positive 40-70%** (always obtain before antibiotics)

**Aspiration/Drainage with Culture:**
- **CT-guided aspiration** (for culture)
- **Gram stain + culture (aerobic, anaerobic, fungal, AFB)**

**Key Point:** **CT with contrast + blood cultures + drainage culture**

---

## TREATMENT

**Drainage vs Splenectomy:**

**Percutaneous CT-Guided Drainage (Preferred if Feasible):**
- **Success rate:** 60-80%
- **Indications:**
  - **Solitary abscess** or **few abscesses**
  - **Unilocular or minimally septated**
  - **Accessible** (safe CT-guided approach)
  - **No complex multiloculation**

**Splenectomy (Definitive):**
- **Success rate:** 85-95%
- **Indications:**
  - **Multiple abscesses** (>3-5 abscesses)
  - **Highly multiloculated** (complex septations)
  - **Failed percutaneous drainage** (persistent after drainage attempt)
  - **Rupture** (peritonitis)
  - **Massive spleen enlargement** (risk of rupture)
  - **Fungal abscess** (less responsive to drainage + medical therapy)
  - **Diagnostic uncertainty** (need tissue for diagnosis)

**Medical Therapy Alone (Rarely Effective):**
- **Small abscess** (<2 cm) + immunocompetent
- **Success rate:** 30-50% (often fails, surgery usually required)

**Key Point:** **Splenectomy = definitive treatment** (85-95% cure) | **Percutaneous drainage = 60-80% success if unilocular**

---

**Antibiotics:**

**Empiric (Until cultures):**

**Immunocompetent (Suspected Endocarditis/Hematogenous):**
- **Vancomycin** 15-20 mg/kg IV q8-12h + **Ceftriaxone** 2g IV q12h
- **Covers:** MRSA, Streptococcus, Gram-negatives

**Immunocompromised (Suspected Fungal):**
- **Empiric antifungal:**
  - **Fluconazole** 400-800mg IV daily (if Candida suspected, stable patient)
  - **Echinocandin** (micafungin, caspofungin) if critically ill or mold concern
  - **Voriconazole** or **amphotericin** (if Aspergillus suspected)
- **+ Antibacterial coverage** (vancomycin + cefepime)

**Contiguous GI Source:**
- **Metronidazole** 500mg IV q6h + **Ceftriaxone** 2g IV q12h OR **Cefepime** 2g IV q8h
- **OR:** Piperacillin-tazobactam 4.5g IV q6h

**Targeted (Based on culture):**
- **MSSA:** Cefazolin or nafcillin
- **MRSA:** Vancomycin or daptomycin
- **Streptococcus:** Penicillin G or ceftriaxone
- **Gram-negatives:** Ceftriaxone or carbapenems
- **Candida:** Fluconazole (if susceptible) or echinocandin
- **Aspergillus:** Voriconazole

**Duration:**
- **Bacterial:** 4-6 weeks IV (if drainage/splenectomy performed)
- **Fungal:** 6-12 weeks (or longer, until resolution on imaging)
- **TB:** 6-12 months (RIPE therapy)

**Key Point:** **Splenectomy + IV antibiotics 4-6 weeks** (most require surgery)

---

## POST-SPLENECTOMY CONSIDERATIONS

**Overwhelming Post-Splenectomy Infection (OPSI):**
- **Risk:** 0.5-2% per year (lifelong risk)
- **Mortality:** 50% (if OPSI occurs)
- **Organisms:** Encapsulated bacteria (S. pneumoniae, H. influenzae, N. meningitidis)

**Vaccination (Mandatory):**
- **Ideally 2 weeks BEFORE splenectomy** (or 2 weeks after if urgent surgery)
- **Pneumococcal:**
  - **PCV20** (Prevnar 20) OR **PCV15 → PPSV23 (1 year later)**
  - **PPSV23 booster** (every 5 years)
- **Haemophilus influenzae type B** (Hib)
- **Meningococcal:**
  - **MenACWY** (Menactra/Menveo)
  - **MenB** (Bexsero/Trumenba)
  - **Boosters** (MenACWY every 5 years, MenB per guidelines)
- **Influenza** (annual)

**Antibiotic Prophylaxis:**
- **Consider:** Penicillin VK 250mg PO bid OR amoxicillin 250mg PO daily (lifelong, controversial)
- **High-risk patients:** Children <5 years, immunocompromised, prior OPSI

**Education:**
- **Seek immediate care** for fever (>100.4°F/38°C)
- **Carry medical alert** card/bracelet (asplenic)

**Key Point:** **Vaccinate 2 weeks before (or after) splenectomy** (pneumococcal, Hib, meningococcal mandatory)

---

## PROGNOSIS

**With Splenectomy + Antibiotics:**
- **Cure rate:** 85-95%
- **Mortality:** 10-30% (even with treatment)

**Without Treatment:**
- **Mortality:** 100% (uniformly fatal)

**Factors Predicting Poor Outcome:**
1. **Delayed diagnosis** (>2-4 weeks)
2. **Immunosuppression** (neutropenia, HIV, transplant)
3. **Multiple abscesses** (worse than solitary)
4. **Fungal infection** (worse than bacterial)
5. **Septic shock at presentation**
6. **Ruptured abscess** (peritonitis)

**Key Point:** **High mortality even with treatment** (10-30%) | **Untreated = 100% fatal**

---

## COMPLICATIONS

**Mnemonic: "RUPTURE-SEPSIS-PLEURAL-DEATH"**

**R**upture (into peritoneum - peritonitis, 5-10%)
**U**ncontrolled sepsis (septic shock)
**P**leural effusion (left - reactive, empyema if ruptures)
**T**hrombocytopenia (splenic sequestration, DIC)
**U**ntreated (100% mortality)
**R**ecurrence (5-10% if inadequate treatment)
**E**xtension (to adjacent organs - pancreas, kidney)

**S**epsis (bacteremia, septic shock - 30-50%)
**E**xtension (to adjacent structures)
**P**eritonitis (if ruptures into peritoneum)
**S**ubphrenic abscess
**I**nadequate drainage (multiloculated)
**S**inus tract (chronic draining - rare)

**P**leural effusion (left - 30-40%, reactive)
**L**eft empyema (if ruptures into pleura)
**E**xtreme complications (rupture, shock)
**U**nhealed abscess (chronic, recurrent)
**R**espiratory (pleural effusion, empyema)
**A**djacent organ involvement
**L**ong-term asplenia (if splenectomy - OPSI risk)

**D**eath (10-30% mortality despite treatment, 100% if untreated)
**E**xtensive tissue loss
**A**bscess recurrence
**T**hrombosis (splenic vein thrombosis)
**H**emorrhage (if erodes into vessels)

**Key Point:** **Rupture (5-10%) → peritonitis or empyema** | **Mortality 10-30% despite treatment**

---

## DIFFERENTIAL DIAGNOSIS

**Other Splenic Lesions:**

**Mnemonic: "ABSCESS-INFARCT-CYST-TUMOR"**

**Abscess:**
- **Rim enhancement** + restricted diffusion + fever + leukocytosis

**Infarct (Splenic Infarction):**
- **Wedge-shaped** (peripheral, follows vascular territory)
- **No enhancement** (vs abscess enhances)
- **Acute onset pain**
- **Underlying thromboembolic source** (endocarditis, atrial fibrillation, sickle cell)

**Cyst (Simple, Hydatid, Pseudocyst):**
- **Thin smooth wall** (vs thick irregular abscess)
- **No enhancement** (simple cyst)
- **Hydatid:** Daughter cysts, serology positive
- **Pseudocyst:** Post-pancreatitis, amylase elevated

**Tumor (Lymphoma, Angiosarcoma, Metastases):**
- **Solid component** (vs fluid abscess)
- **Enhances solidly** (vs rim-enhancing abscess)
- **No diffusion restriction** (vs abscess restricts)

**Hematoma (Post-Trauma):**
- **History of trauma**
- **High T1 signal** (blood products if subacute)
- **No enhancement** (vs abscess enhances)

**Key Point:** **Rim enhancement + restricted diffusion + fever = abscess** (vs infarct/cyst/tumor)

---

**Clinical Pearls:**
- **Splenic abscess = rare but life-threatening** (10-30% mortality despite treatment, 100% if untreated)
- **Multiloculated rim-enhancing hypodense lesion = hallmark** (50-70% multiloculated)
- **Immunocompromised = #1 risk factor** (50-70%)
- **Endocarditis = #1 cause in immunocompetent** (septic emboli)
- **Hematogenous = most common route** (60-70%)
- **Fever + LUQ pain + tender splenomegaly = splenic abscess**
- **S. aureus, Strep most common** (immunocompetent) | **Candida, Aspergillus** (immunocompromised)
- **CT with contrast = gold standard** (90-95% sensitive)
- **Splenectomy = definitive treatment** (85-95% cure)
- **Percutaneous drainage = 60-80% success** (if unilocular, few abscesses)
- **Medical therapy alone rarely effective** (30-50% success)
- **Post-splenectomy: Vaccinate** (pneumococcal, Hib, meningococcal) + OPSI risk (0.5-2% per year)

**Media:**

**Additional Resources:**
- **Radiopaedia.org:** Search "splenic abscess"
- **PMC:** Splenic abscess imaging and management
- **Splenectomy Guidelines:** Post-splenectomy vaccination protocols

**Sources:** [Radiopaedia - Splenic Abscess], [PMC - Splenic Infections], [CDC Post-Splenectomy Vaccination Guidelines]
